Clinical Trials Logo

Limb Girdle Muscular Dystrophy clinical trials

View clinical trials related to Limb Girdle Muscular Dystrophy.

Filter by:

NCT ID: NCT06246513 Recruiting - Clinical trials for Limb-girdle Muscular Dystrophy

A Trial to Learn More About an Experimental Gene Therapy Called Bidridistrogene Xeboparvovec (SRP-9003) as a Possible Treatment for Limb Girdle Muscular Dystrophy 2E/R4 (EMERGENE)

Start date: January 15, 2024
Phase: Phase 3
Study type: Interventional

This is a multicenter, global study of the effects of a single systemic dose of SRP-9003 on beta-sarcoglycan (β-SG) gene expression in participants with limb-girdle muscular dystrophy, type 2E/R4 (LGMD2E/R4). This study will consist of both ambulatory participants (Cohort 1) and non-ambulatory participants (Cohort 2).

NCT ID: NCT05906251 Active, not recruiting - Clinical trials for Limb Girdle Muscular Dystrophy

A Gene Transfer Study to Evaluate the Safety, Tolerability and Efficacy of SRP-6004 in Ambulatory Participants With Limb Girdle Muscular Dystrophy, Type 2B/R2 (LGMD2B/R2, Dysferlin [DYSF] Related)

Start date: May 22, 2023
Phase: Phase 1
Study type: Interventional

The primary purpose of this study is to evaluate the safety of SRP-6004 administered by intravenous (IV) infusion in ambulatory participants with LGMD2B/R2 (DYSF related).

NCT ID: NCT05876780 Active, not recruiting - Clinical trials for Limb Girdle Muscular Dystrophy

A Gene Transfer Single Dose Study to Evaluate the Safety, Tolerability and Efficacy of SRP-9003 in Non-Ambulatory and Ambulatory Participants With Limb Girdle Muscular Dystrophy, Type 2E/R4 (Beta-Sarcoglycan [β-SG] Deficiency)

Start date: December 19, 2022
Phase: Phase 1
Study type: Interventional

The primary purpose of this study is to evaluate the safety of SRP-9003 and to quantify expression of β-SG in the skeletal muscle of participants with limb-girdle muscular dystrophy, type 2E/R4 (LGMD2E/R4). The study will include both ambulatory (Cohort 1) and non-ambulatory (Cohort 2) participants.

NCT ID: NCT05618080 Recruiting - Clinical trials for Limb Girdle Muscular Dystrophy

Trial Readiness and Endpoint Assessment in LGMD R1

GRASP-01-003
Start date: January 31, 2024
Phase:
Study type: Observational

This is a 24-month, observational study of 100 participants with Limb Girdle Muscular Dystrophy type R1, also known as CAPN3.

NCT ID: NCT05409079 Recruiting - Cerebral Palsy Clinical Trials

Schulze Muscular Dystrophy Ability Clinical Study

Start date: May 26, 2022
Phase: N/A
Study type: Interventional

The primary objective of the Schulze study is to evaluate the function of the upper limbs of subjects diagnosed with neuromuscular disorders, with and without use of the Abilitech Assist device in the clinic and home environments. Functional outcomes will include documenting active range of motion and the ability to perform activities of daily living (ADLs) using the standardized Canadian Occupational Performance Measure (COPM) and the Role Evaluation of Activities of Life (REAL) assessments. Secondary objectives are to assess the safety record and report on adverse events (AEs) and parameters related to device usage, including device usage time and the time required to don/doff the device. Secondary objectives also include characterization of user upper limb performance based on etiology.

NCT ID: NCT05230459 Recruiting - Muscular Dystrophy Clinical Trials

A Study to Evaluate the Safety of AB-1003 (Previously LION-101) in Subjects With Genetic Confirmation of LGMD2I/R9 (Part1)

Start date: March 12, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety and tolerability of a single intravenous infusion of AB-1003 in adults diagnosed with limb girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). Participants will be treated in sequential, dose-level cohorts. (Part 1)

NCT ID: NCT05206617 Active, not recruiting - Clinical trials for Neuromuscular Diseases

3 Year Follow up on ANO5 Patients

Start date: January 1, 2018
Phase:
Study type: Observational

The aim of the study is to investigate progression in muscle affection in patients with pathogenic variants in the anoctamin 5 gene to: 1. investigate possible progression of disease over time 2. investigate good and reliable outcome measures

NCT ID: NCT05102799 Recruiting - Clinical trials for Limb Girdle Muscular Dystrophy

MRI-phenotyping of Patients With Pathogenic Anoctamin 5 Variants

ANO5 MRI
Start date: April 1, 2021
Phase:
Study type: Observational

A large cohort of MRI scans from patients with pathogenic variants in the anoctamin 5 gene will be collected through an international collaboration to better describe muscle involvement.

NCT ID: NCT04475926 Recruiting - Clinical trials for Limb-girdle Muscular Dystrophy

A Study of the Natural History of Participants With LGMD2E/R4, LGMD2D/R3, LGMD2C/R5, and LGMD2A/R1 ≥ 4 Years of Age, Who Are Managed in Routine Clinical Practice

Start date: April 22, 2021
Phase:
Study type: Observational

This study will follow participants who are screened and confirmed with a genetic diagnosis of Limb-girdle muscular dystrophy type 2E (LGMD2E/R4), Limb-girdle muscular dystrophy type 2D (LGMD2D/R3), Limb-girdle muscular dystrophy type 2C (LGMD2C/R5), or Limb-girdle muscular dystrophy type 2A (LGMD2A/R1). These enrolled participants will be followed to evaluate mobility and pulmonary function for up to 3 years after enrollment. Additional participant data will be collected from the time the individual began experiencing LGMD symptoms to the present.

NCT ID: NCT04202627 Completed - Clinical trials for Muscular Dystrophies

Biomarker Development in LGMD2i

MLB-01-001
Start date: December 1, 2019
Phase:
Study type: Observational

The overall goal of this natural history study is to define the key LGMD2i phenotypes as measured by standard clinical outcome assessments (COAs), and to validate a muscle biomarker for LGMD2i to support therapeutic development.